Paclitaxel for Injection (Albumin Bound) for patients with malignant tumor: a multicenter, real-world study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400083939

Enrollment

Unknown

Registered

2024-05-08

Start date

2024-05-15

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

Case series:NA

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age =18 years old; 2. Patients with malignant tumors confirmed by histopathology or cytology, including breast cancer, ovarian cancer, lung cancer, cervical cancer, pancreatic cancer, liver cancer, stomach cancer, etc. can be included in this study after self-evaluation by the researchers; 3. The researchers evaluated the use of paclitaxel for injection (Albumin Bound) therapy; 4. All participants provided written informed consent before screening.

Exclusion criteria

Exclusion criteria: 1. The patient is undergoing or planning to enroll in another clinical study; 2. Allergic to albumin-bound paclitaxel components; 3. Other situations deemed unsuitable for inclusion in the study by the researcher.

Design outcomes

Primary

Measure	Time frame
safety;	—

Secondary

Measure	Time frame
progression-free survival;overall suriviva;	—

Countries

China

Contacts

Public ContactLUO JING

Sichuan Academy of Medical Sciences · Sichuan Provincial People's Hospital

weixiao_smile@yeah.net+86 189 8183 8521

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026